Your browser doesn't support javascript.
loading
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index.
Persano, Mara; Rimini, Margherita; Tada, Toshifumi; Suda, Goki; Shimose, Shigeo; Kudo, Masatoshi; Cheon, Jaekyung; Finkelmeier, Fabian; Lim, Ho Yeong; Presa, José; Masi, Gianluca; Yoo, Changhoon; Lonardi, Sara; Pressiani, Tiziana; Piscaglia, Fabio; Kumada, Takashi; Rimassa, Lorenza; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea.
Affiliation
  • Persano M; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Rimini M; Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy; margherita.rimini@gmail.com.
  • Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Suda G; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Shimose S; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Cheon J; Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
  • Finkelmeier F; Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
  • Lim HY; Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea.
  • Presa J; Liver Unit-CHTMAD, Vila Real, Portugal.
  • Masi G; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Yoo C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Lonardi S; Department of Oncology, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Pressiani T; Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Piscaglia F; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Kumada T; Division of Internal Medicine, Hepatobiliary and Immunoallergic diseases, University of Bologna, Bologna, Italy.
  • Rimassa L; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
  • Scartozzi M; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Cascinu S; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Casadei-Gardini A; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
Anticancer Res ; 43(4): 1599-1610, 2023 04.
Article in En | MEDLINE | ID: mdl-36974779
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Res Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Anticancer Res Year: 2023 Document type: Article Affiliation country: Country of publication: